193 related articles for article (PubMed ID: 28604257)
21. Potential significance of antiestrogen therapy in the development of bisphosphonate related osteonecrosis of the jaw.
Vaszilko M; Kovacs E; Restar L; Balla B; Cseplo K; Kosa J; Lakatos P
J Craniomaxillofac Surg; 2014 Dec; 42(8):1932-6. PubMed ID: 25316650
[TBL] [Abstract][Full Text] [Related]
22. Intravenous bisphosphonate therapy and bisphosphonate-related osteonecrosis of the jaws.
Dodson TB
J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):44-52. PubMed ID: 19371814
[TBL] [Abstract][Full Text] [Related]
23. Mesenchymal stromal cells administration for osteonecrosis of the jaw caused by bisphosphonate: report of two cases.
De Santis GC; de Macedo LD; Orellana MD; Innocentini LMAR; Ferrari TC; Ricz HMA; Caruso SR; Fernandes TR; Covas DT
Acta Oncol; 2020 Jul; 59(7):789-792. PubMed ID: 32079438
[No Abstract] [Full Text] [Related]
24. Altered microRNA expression profile in the peripheral lymphoid compartment of multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw.
Musolino C; Oteri G; Allegra A; Mania M; D'Ascola A; Avenoso A; Innao V; Allegra AG; Campo S
Ann Hematol; 2018 Jul; 97(7):1259-1269. PubMed ID: 29546453
[TBL] [Abstract][Full Text] [Related]
25. Preventive effect of tetrahedral framework nucleic acids on bisphosphonate-related osteonecrosis of the jaw.
Cui W; Chen X; Zhu J; Zhang M; Xiao D; Qin X; Zhang T; Lin Y
Nanoscale; 2020 Aug; 12(33):17196-17202. PubMed ID: 32667372
[TBL] [Abstract][Full Text] [Related]
26. Incidence of bisphosphonate-related osteonecrosis of the jaw in consideration of primary diseases and concomitant therapies.
Assaf AT; Smeets R; Riecke B; Weise E; Gröbe A; Blessmann M; Steiner T; Wikner J; Friedrich RE; Heiland M; Hoelzle F; Gerhards F
Anticancer Res; 2013 Sep; 33(9):3917-24. PubMed ID: 24023329
[TBL] [Abstract][Full Text] [Related]
27. Bisphosphonate-related osteonecrosis of the jaw in patients with oral bisphosphonate exposure: clinical course and outcomes.
O'Ryan FS; Lo JC
J Oral Maxillofac Surg; 2012 Aug; 70(8):1844-53. PubMed ID: 22595135
[TBL] [Abstract][Full Text] [Related]
28. Immune-related expression profiles of bisphosphonates-related osteonecrosis of the jaw in multiple myeloma.
He J; Zhou Q; Jia X; Zhou P; Chen L
Pharmazie; 2021 Apr; 76(4):159-164. PubMed ID: 33849701
[No Abstract] [Full Text] [Related]
29. Gene expression analysis of fresh extraction wounds prior to onset of bisphosphonate-related osteonecrosis of the jaw-like lesions in mice: A preliminary animal study.
Kuroshima S; Nakajima K; Sasaki M; Hayano H; Inoue M; Kozutsumi R; Sawase T
J Prosthodont Res; 2021 Oct; 65(4):546-553. PubMed ID: 33840704
[TBL] [Abstract][Full Text] [Related]
30. Occurrence of bisphosphonate-related osteonecrosis of the jaw after surgical tooth extraction.
Saia G; Blandamura S; Bettini G; Tronchet A; Totola A; Bedogni G; Ferronato G; Nocini PF; Bedogni A
J Oral Maxillofac Surg; 2010 Apr; 68(4):797-804. PubMed ID: 20307765
[TBL] [Abstract][Full Text] [Related]
31. New approach to analyze genetic and clinical data in bisphosphonate-induced osteonecrosis of the jaw.
Balla B; Vaszilko M; Kósa JP; Podani J; Takács I; Tóbiás B; Nagy Z; Lazáry A; Lakatos P
Oral Dis; 2012 Sep; 18(6):580-5. PubMed ID: 22339777
[TBL] [Abstract][Full Text] [Related]
32. Identification of Potential Biomarkers and Small Molecule Drugs for Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ): An Integrated Bioinformatics Study Using Big Data.
Balachandran K; Ramli R; Karsani SA; Abdul Rahman M
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239981
[TBL] [Abstract][Full Text] [Related]
33. Incidence and risk factors of bisphosphonate-related osteonecrosis of the jaw in multiple myeloma patients having undergone autologous stem cell transplantation.
Then C; Hörauf N; Otto S; Pautke C; von Tresckow E; Röhnisch T; Baumann P; Schmidmaier R; Bumeder I; Oduncu FS
Onkologie; 2012; 35(11):658-64. PubMed ID: 23147542
[TBL] [Abstract][Full Text] [Related]
34. Surgical management of bisphosphonate-related osteonecrosis of the jaw stages II and III.
Bodem JP; Schaal C; Kargus S; Saure D; Mertens C; Engel M; Hoffmann J; Freudlsperger C
Oral Surg Oral Med Oral Pathol Oral Radiol; 2016 Apr; 121(4):367-72. PubMed ID: 26795450
[TBL] [Abstract][Full Text] [Related]
35. Zoledronate treatment duration is linked to bisphosphonate-related osteonecrosis of the jaw prevalence in rice rats with generalized periodontitis.
Messer JG; Jiron JM; Mendieta Calle JL; Castillo EJ; Israel R; Phillips EG; Yarrow JF; Van Poznak C; Kesavalu L; Kimmel DB; Aguirre JI
Oral Dis; 2019 May; 25(4):1116-1135. PubMed ID: 30712276
[TBL] [Abstract][Full Text] [Related]
36. Experimental investigation of relationship between trauma and bisphosphonate-related osteonecrosis.
Agaçayak KS; Yuksel H; Atilgan S; Koparal M; Uçan MC; Ozgöz M; Yaman F; Atalay Y; Acikan I
Niger J Clin Pract; 2014; 17(5):559-64. PubMed ID: 25244263
[TBL] [Abstract][Full Text] [Related]
37. Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.
Tan M; Kalin-Hajdu E; Narayan R; Wong SW; Martin TG
J Oncol Pharm Pract; 2019 Jul; 25(5):1253-1257. PubMed ID: 30005587
[TBL] [Abstract][Full Text] [Related]
38. Risk factors for developing osteonecrosis of jaw in advanced cancer patients underwent zoledronic acid treatment.
Qi WX; Zhao S; Chen J
Future Oncol; 2019 Oct; 15(30):3503-3511. PubMed ID: 31580147
[No Abstract] [Full Text] [Related]
39. Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: A trigger for BRONJ development?
Otto S; Tröltzsch M; Jambrovic V; Panya S; Probst F; Ristow O; Ehrenfeld M; Pautke C
J Craniomaxillofac Surg; 2015 Jul; 43(6):847-54. PubMed ID: 25958767
[TBL] [Abstract][Full Text] [Related]
40. Bioinformatic Data Mining for Candidate Drugs Affecting Risk of Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) in Cancer Patients.
Zhuang J; Zu J; Zhou C; Sun Y; Kong P; Jing Y
Dis Markers; 2022; 2022():3348480. PubMed ID: 36157219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
